Hearscape
← Therapeutics
Details checkedStatus needs checkingCheckedcompany

AK-CLRN1 by Eli Lilly

Also known as: AK-CLRN1

Eli Lilly and Company

Primary source
Company
Eli Lilly and Company
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Preclinical
Status
Unknown
Target Gene
CLRN1
Route / Mode
Unknown
Confidence
80%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
United States
Population
genetic, pediatric, post-lingual
Trial IDs
0
Mechanism

AAV-based inner-ear gene therapy intended to restore CLRN1 expression for Usher syndrome type 3A-associated hearing loss.

Indications
Hearing LossSensorineural Hearing LossGenetic Hearing Loss
Notes

Verified as a real Akouos-originated AK-CLRN1 program for Usher syndrome type 3A-associated hearing loss acquired by Lilly. Lilly's current public clinical pipeline page is dated April 30, 2026 and does not disclose this preclinical asset or a program-specific development status; HearScape therefore verifies existence and ownership while keeping public current status as Unknown.

Evidence & Sources
3 structured sources
company
Supports: canonicalName, company, allCompanies, modality, targetGene, indications, stage, notes
IDs: AK-CLRN1, CLRN1
Open
company
Supports: modality, mechanism, targetGene, indications, stage, populationTags
IDs: AK-CLRN1, CLRN1
Open
company
Supports: notes, status
Open
Key Events
2020-03-19
Akouos S-1 described AK-CLRN1 and preclinical rationale
2022-10-18
Lilly announced the Akouos acquisition and listed AK-CLRN1 among additional pipeline programs
2026-04-30
Lilly clinical pipeline page current as of this date does not disclose a program-specific AK-CLRN1 status
Data Checks
current-status-not-publicly-disclosedroute-not-publicly-disclosedpost-acquisition-programpreclinical-status-caveated
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2